The table below shows EU regulatory developments in the biosimilars area since 2018. It covers new product filings with the European Medicines Agency, opinions from the EMA’s drug evaluation committee, the CHMP, withdrawals of marketing authorization applications (MAAs), and decisions on biosimilar marketing authorizations by the European Commission.
The latest update of the table, compiled on 22 April, includes among other things the approval of new biosimilar versions of pegfilgrastim and aflibercept, from CuraTeQ Biologics and Amgen respectively, and Henlius
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?